PCI in Patients with Diabetes: Role of the Cre8 Drug-eluting Stent.

Détails

ID Serval
serval:BIB_3FB46E47FC22
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
PCI in Patients with Diabetes: Role of the Cre8 Drug-eluting Stent.
Périodique
Interventional cardiology
Auteur(s)
Byrne R.A., Eeckhout E., Sardella G., Stella P., Verheye S.
ISSN
1756-1477 (Print)
ISSN-L
1756-1485
Statut éditorial
Publié
Date de publication
05/2017
Peer-reviewed
Oui
Volume
12
Numéro
1
Pages
13-17
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: ppublish
Résumé
Patients with diabetes have poor outcomes compared to the general patient population when undergoing percutaneous coronary intervention. The Cre8™ (Alvimedica) drug-eluting stent (DES) has unique features that may improve clinical outcomes in patients with diabetes. These include abluminal reservoir technology, a proprietary polymer-free drug-release system consisting of reservoirs on the stent's outer surface that control and direct drug release exclusively towards the vessel wall, and the Amphilimus™ formulation, which enables enhanced drug tissue permeation, utilising fatty acid transport pathways. This is particularly advantageous in diabetic patients, since increased uptake of fatty acid occurs in diabetic cells. Furthermore, mTOR inhibitors (-limus drugs), which are utilised in DESs, are relatively ineffective in diabetic cells. Clinical efficacy and safety of the Cre8™ in patients with diabetes has been demonstrated in a number of clinical trials and real-world studies, and further studies are on-going.

Mots-clé
Coronary artery disease, diabetes, drug-eluting stent, percutaneous coronary intervention
Pubmed
Création de la notice
29/03/2018 18:12
Dernière modification de la notice
10/04/2018 6:26
Données d'usage